OPKO Health swings to Q3 net loss of $53.5 million; Q3 revenue rises 16% to $65.4 million

By Public Technologies
  • OPKO Health swung to a third-quarter 2026 net loss of $53.5 million from net income of $21.6 million a year earlier.
  • Continuing operations revenue rose 16% to $65.4 million, primarily due to higher Lilly royalties, increased Rayaldee sales and international growth.
  • Agreed to sell substantially all remaining BioReference operations to Labcorp for $722 million at closing and up to $150 million additionally.
  • Projected continuing operations revenue of $62 million to $72 million for the three months ending December 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041623PRIMZONEFULLFEED9870587) on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.